Methotrexate in Ankylosing Spondylitis (MTX in AS)
Recruitment status was Active, not recruiting
Assessing the efficacy and tolerability of methotrexate 15mg sc in the first month of treatment- if well tolerated methotrexate 20mg sc in the following 3 months in patients with active anklyosing spondylitis
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Educational/Counseling/Training
|Official Title:||Open Study for the Evaluation of the Efficacy of Methotrexate 20mg Given Subcutaneously in Patients With Active Ankylosing Spondylitis|
- improvement of disease activity parameters according to ASAS - 20% response
- improvement of BASDAI, of pain on a scale from 0-10, reduction of CRP/ ESR (inflammatory serum parameters), reduction of BASFI, BASMI, number of swollen and tender joints, number of enthesitic locations, improvement of life quality.
|Study Start Date:||September 2003|
|Estimated Study Completion Date:||November 2005|
Ankylosing spondylitis is an inflammatory rheumatic disease mit main affection of the spine. However peripheral joints, entheses and the eyes can also be affected. The rheumatic symptoms of the patients typically show good response to nonsteroidal antirheumatic drugs.
In contrast to rheumatoid arthritis in ankylosing spondylitis there is no evidence that therapy with disease modifying antirheumatic drugs is effective (DMARD). Next to studies with the DMARD sulfasalazine, which seems to be effective mainly in peripheral joint involvement and in which a possible effect in short disease duration also seems to exist for axial involvement, in regards of other DMARDs there are only small studies or case reports.
In terms of methotrexate only small studies with a dosage of 7,5mg – 10 mg – maximally 15mg (perorally in single patients) have been published. In three open studies in 11- 34 patients treated with methotrexate 7,5mg – maximally 15mg perorally over a time duration of 24 weeks until maximally 3 years there a certain effectiveness partly in spinal symptoms, partly in peripheral joint involvement (1, 2, 3). In both double blind controlled studies with 30 and 50 patients respectively with a dosage of 7,5 and 10mg methotrexate respectively no significant effectiveness was shown (4,5). To summarize, in the different studies no effectiveness could be shown clearly.
Therapy with methotrexate in patients with inflammatory rheumatic diseases – especially in rheumatoid arthritis- belongs to standard therapy. In Germany methotrexate is given in about 70% of cases because of its good effectiveness as therapy of first choice. In the treatment of psoriatic arthritis representing a disease which is similar to ankylosing spondylitis in regards to pathogenesis, methotrexate therapy could be established in a dosage of 20mg parenterally and 25mg perorally respectively successfully. Bearing this in mind it is even more surprising that there are no data about methotrexate in this dosages for the treatment of ankylosing spondylitis. According to the German rheumatic register (so-called “rheumatologische Kerndokumentation“, PD. Dr. A. Zink, DRFZ, Berlin) already about 20% of patients with ankylosing spondylitis are treated with methotrexate by German rheumatologists. For this reason it is makes sense to perform a study for the treatment of patients with active ankylosing spondylitis with methotrexate in a dosage of 20mg. In the therapy of rheumatoid arthritis a combination of methotrexate and TNFalpha blocking agents leads to an enhancement of effectiveness and reduction of side effects. For this reason the effectivenss of methotrexate in ankylosing spondylitis is also very interesting in regards to a possible combination with TNFalpha blocking agents which have shown to be very successful in the treatment of ankylosing spondyltitis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00243750
|Charité Campus Benjamin-Franklin, Rheumatology|
|Berlin, Germany, 12200|
|Principal Investigator:||Joachim Sieper, Prof.||Charité Campus Benjamin-Franklin, Rheumatology|